Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
Conditions: Connective Tissue Diseases; Thrombocytopenia Interventions: Biological: Telitacicept; Drug: Placebo Sponsors: Beijing Hospital; The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial); Peking University People's Hospital; Peking University Third Hospital; First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People's Hospital; The First Affiliated Hospital of Zhengzhou University; Wuhan Union Hospital, China; Second Xiangya Hospital of Central South University; Xiangya Hospital of Central South University; The Affiliated Hospital of Inner Mongolia Medical University; First Hospital of China Medical University; Shandong Provincial Hospital; Changhai Hospital; RenJi Hospital; Shanxi Bethune Hospital; West China Hospital; Institute of Hematology & Blood Diseases Hospital; Tianjin First Central Hospital; Tianjin Medical University General Hospital; People's Hospital of Xinjiang Uygur Autonomous Region; The First People's Hospital of Yunnan Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: China Health | Hematology | Hospitals | Mongolia Health | Research | Science | Thrombocytopenia